American Regent v. Gland Pharma: Selenious Acid Patent Case Consolidated in 21 Days
American Regent, Inc. filed suit against Gland Pharma, Ltd. in the District of New Jersey asserting US12150957B2, a patent covering selenious acid injectable selenium formulations. The case was resolved administratively in just 21 days — not on the merits — when it was consolidated into a broader parallel action, with all future filings to proceed under a unified caption.
ANDA Selenium Injection Dispute Folded Into Consolidated Proceedings
On December 13, 2024, American Regent, Inc. filed an infringement action against Gland Pharma, Ltd. in the United States District Court for the District of New Jersey (Case No. 2:24-cv-11116). The suit asserted US12150957B2, a patent covering selenious acid injectable formulations used as intravenous selenium supplements, specifically targeting Gland Pharma’s proposed generic products at three concentration levels: 600 mcg/10 mL, 60 mcg/mL, and 6 mcg/mL (2 mL). This type of action is characteristic of Hatch-Waxman ANDA patent litigation, where a brand manufacturer challenges a generic filer’s attempt to market a bioequivalent product before patent expiry.
The case was closed on January 3, 2025 — just 21 days after filing — when the court ordered it consolidated into a related parallel action. The consolidation order directed that all future filings use a unified caption, consistent with standard practice when multiple ANDA cases involving the same patent and product are pending before the same court. No merits ruling, claim construction, or injunction decision was issued. The case’s substantive questions — whether Gland Pharma’s ANDA product infringes US12150957B2 and whether the patent is valid — remain live within the consolidated proceeding.
The 21-day resolution window reflects purely administrative efficiency rather than any substantive outcome for either party. Consolidation of related ANDA matters is common in the District of New Jersey, one of the most active venues for pharmaceutical patent litigation in the United States. What the public record does not reveal is which other cases were folded into the consolidated action, the identity of any co-plaintiffs or co-defendants in the broader proceeding, or the current procedural posture of the consolidated matter. Parties and observers should monitor the consolidated docket for substantive developments.
Filing to Case Consolidated in 21 days
Resolved by consolidation — 21 days from filing to administrative closure, far below the typical 2–3 year ANDA litigation timeline
Case consolidated: what the order means and what happens next
Consolidation is procedural — the dispute is not resolved
A consolidation order under Fed. R. Civ. P. 42(a) merges related cases sharing common questions of law or fact into a single proceeding. The court’s instruction that ‘all filings shall continue use the following caption going forward’ is a standard administrative directive. It does not dismiss any claim, resolve any patent question, or grant any party a substantive advantage. The underlying infringement and validity questions remain fully live.
No merits adjudicationAmerican Regent’s infringement claims survive consolidation intact
Consolidation does not prejudice American Regent’s ability to enforce US12150957B2. The patent’s claims covering selenious acid injectable selenium formulations remain asserted against Gland Pharma’s proposed ANDA products. American Regent may benefit from consolidated proceedings if the same patent is being litigated against multiple generic filers simultaneously, potentially achieving a single, binding ruling on validity and infringement.
Claims remain activeGland Pharma faces coordinated litigation in a consolidated forum
Consolidation typically means Gland Pharma will defend its ANDA in a proceeding that may include other generic challengers. This can reduce duplicative discovery costs but also means that an adverse validity or infringement ruling in the consolidated case would bind all defendants. The 30-month statutory stay on FDA approval of Gland Pharma’s ANDA product continues to run from the original notice letter date regardless of consolidation.
30-month stay continuesSelenium IV market access delayed pending consolidated outcome
Intravenous selenious acid products are critical micronutrient supplements used in parenteral nutrition. Gland Pharma’s ability to enter the U.S. market with a lower-cost generic hinges on the consolidated litigation outcome. Until US12150957B2 is either invalidated or a non-infringement finding is secured, generic market entry is blocked. Brand manufacturers in the IV micronutrient space should monitor the consolidated docket closely as a precedent-setting proceeding.
Generic entry on holdFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | American Regent, Inc. | Company | Pharmaceutical company — holder of US12150957B2 covering injectable selenious acid formulationsSearch in Eureka ↗ |
| Defendant | Gland Pharma, Ltd. | Company | Indian generic pharmaceutical manufacturer filing ANDA for selenious acid selenium injection productsSearch in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christine A. Gaddis | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s directive that ‘all filings in the Consolidated Action shall continue use the following caption going forward’ is a purely procedural disposition. It carries no merits weight — no finding of infringement, validity, or invalidity is made. The verdict cause of ‘Infringement Action’ reflects the original pleading basis, not a final adjudication. Both parties’ substantive rights are fully preserved within the consolidated proceeding, and the litigation remains ongoing.
US12150957B2 — Selenious Acid Injectable Selenium Formulations
US12150957B2, filed under application number US18/672876, protects selenious acid injectable formulations used as intravenous selenium supplements. The patent covers specific concentration configurations — including 60 mcg selenium/mL and 6 mcg selenium/mL presentations — that are administered as part of parenteral nutrition regimens. Selenium is an essential trace element, and IV formulations are critical for patients unable to absorb nutrients enterally. The patent’s issuance number (12,150,957) suggests a relatively recent grant in the current patent cycle, consistent with a formulation or composition patent protecting a branded IV product.
For the IV pharmaceutical sector, formulation patents on established micronutrients like selenium represent a key lifecycle management strategy. By securing patent protection on specific concentration levels, dosage forms, or excipient combinations, brand manufacturers can extend market exclusivity beyond the core compound’s patent life. US12150957B2 is now the subject of consolidated ANDA litigation in the District of New Jersey, making its validity and claim scope a matter of significant commercial interest for any generic manufacturer seeking to enter the IV selenium market. Competitors should monitor claim construction developments in the consolidated proceeding.
Should you run an FTO analysis against US12150957B2?
Any generic pharmaceutical company, contract manufacturer, or parenteral nutrition product developer working with intravenous selenious acid formulations — particularly at or near the 60 mcg/mL or 6 mcg/mL concentration levels — should treat US12150957B2 as a potential freedom-to-operate barrier. The patent is actively asserted in consolidated ANDA proceedings in the District of New Jersey, and its claim scope has not yet been construed by the court. R&D and regulatory teams planning ANDA filings or formulation development programs should assess their exposure now, before any adverse claim construction ruling is issued in the consolidated action.
PatSnap Eureka’s FTO Search Agent can map US12150957B2’s claim landscape, identify prior art bearing on validity, and surface related American Regent patents that may form a broader enforcement thicket around injectable selenium products. Eureka’s analytics can also flag other ANDA filers who may be co-defendants in the consolidated proceeding — providing competitive intelligence on who else is challenging this patent and on what grounds. This enables your IP team to anticipate invalidity arguments already in play and sharpen your own position accordingly.
Run a freedom-to-operate analysis on US12150957B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA Patent Cases: IV Pharmaceutical Formulations in New Jersey
Cases below involve Hatch-Waxman infringement actions over injectable pharmaceutical formulation patents litigated in the District of New Jersey.
What this case signals for the IV pharmaceutical patent IP landscape
This consolidation reflects a broader pattern of coordinated ANDA enforcement by brand pharma players in New Jersey federal courts.
District of New Jersey remains the dominant venue for ANDA patent disputes
The District of New Jersey handles more Hatch-Waxman ANDA patent cases than any other U.S. district. Consolidation of related cases involving the same patent and product is routine here, which can accelerate the path to a single binding ruling on validity — a double-edged outcome for brand manufacturers holding multiple formulation patents.
Formulation patents on established drugs face heightened invalidity risk
US12150957B2 covers selenious acid injectable formulations — a well-established active ingredient. Generic challengers in consolidated ANDA proceedings commonly advance obviousness and prior art arguments against formulation patents. Brand holders should prepare robust secondary-consideration evidence and ensure prosecution history is fully documented before trial.
American v Gland — key questions answered
The case was closed after 21 days when it was consolidated into a broader parallel proceeding. American Regent filed suit on December 13, 2024, asserting US12150957B2 against Gland Pharma’s proposed generic selenious acid injectable products. No merits ruling was issued; the court ordered all filings to proceed under a unified consolidated caption.
US12150957B2 (application no. US18/672876) covers selenious acid injectable formulations used as intravenous selenium supplements, specifically at concentrations including 60 mcg selenium/mL and 6 mcg selenium/mL. These formulations are used in parenteral nutrition for patients requiring IV micronutrient supplementation.
Consolidation under Fed. R. Civ. P. 42(a) merges related cases sharing common legal or factual questions. It does not resolve any claim or dismiss the suit. Gland Pharma’s ANDA for selenious acid injection products remains challenged; the litigation continues in the consolidated proceeding. The 30-month Hatch-Waxman statutory stay on FDA approval continues to run.
Based on the public record, the case consolidation does not affect the 30-month statutory stay triggered under the Hatch-Waxman Act when American Regent filed its infringement suit. The stay runs from the date of Gland Pharma’s Paragraph IV certification notice letter and continues regardless of how the case caption is restructured by consolidation.
The District of New Jersey is the most active venue in the United States for Hatch-Waxman ANDA patent litigation, attracting cases from major brand pharmaceutical companies. Consolidation of related ANDA matters in this district is common when the same patent is asserted against multiple generic filers, suggesting American Regent may be pursuing a coordinated enforcement strategy against several ANDA applicants simultaneously.
PatSnap Eureka searches patents and litigation data to answer instantly.